Neos Therapeutics (NASDAQ:NEOS) was downgraded by BMO Capital Markets from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Wednesday.
A number of other equities analysts have also commented on the stock. Cantor Fitzgerald set a $20.00 price target on shares of Neos Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 1st. Wells Fargo & Co set a $14.00 price target on shares of Neos Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 18th. Zacks Investment Research raised shares of Neos Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a report on Wednesday, October 18th. BidaskClub raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Finally, Cowen reissued a “buy” rating on shares of Neos Therapeutics in a report on Thursday, October 26th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $14.00.
Neos Therapeutics (NASDAQ NEOS) traded down $0.58 during trading on Wednesday, reaching $10.52. 403,280 shares of the company were exchanged, compared to its average volume of 349,448. The company has a quick ratio of 2.14, a current ratio of 2.42 and a debt-to-equity ratio of 4.01. The company has a market cap of $327.67, a price-to-earnings ratio of -3.08 and a beta of -0.74. Neos Therapeutics has a twelve month low of $4.85 and a twelve month high of $13.15.
Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new position in shares of Neos Therapeutics in the 3rd quarter worth $120,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Neos Therapeutics in the 2nd quarter valued at $118,000. New York State Common Retirement Fund boosted its stake in shares of Neos Therapeutics by 67.3% in the 3rd quarter. New York State Common Retirement Fund now owns 17,400 shares of the company’s stock valued at $159,000 after purchasing an additional 7,000 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Neos Therapeutics in the 2nd quarter valued at $146,000. Finally, Rhumbline Advisers boosted its stake in shares of Neos Therapeutics by 13.6% in the 2nd quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after purchasing an additional 2,441 shares in the last quarter. 45.74% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Neos Therapeutics (NEOS) Rating Lowered to Market Perform at BMO Capital Markets” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/31/neos-therapeutics-neos-market-perform-rating-reiterated-at-bmo-capital-markets.html.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.